New diabetes drugs

There are several new diabetes drugs that have been approved by regulatory authorities in recent years. Here are some examples:

  1. SGLT-2 inhibitors:
    • Farxiga (dapagliflozin) - approved in 2014
    • Invokana (canagliflozin) - approved in 2013
    • Jardiance (empagliflozin) - approved in 2014
    • Steglatro (ertugliflozin) - approved in 2017
    • Zynquista (sotagliflozin) - approved in 2019
  2. GLP-1 receptor agonists:
    • Trulicity (dulaglutide) - approved in 2014
    • Victoza (liraglutide) - approved in 2010
    • Saxenda (liraglutide) - approved in 2014 (for weight loss)
    • Ozempic (semaglutide) - approved in 2017
    • Wegovy (semaglutide) - approved in 2021 (for weight loss)
  3. DPP-4 inhibitors:
    • Januvia (sitagliptin) - approved in 2006
    • Onglyza (saxagliptin) - approved in 2009
    • Tradjenta (linagliptin) - approved in 2011
    • Nesina (alogliptin) - approved in 2011
  4. SGLT-1 inhibitors:
    • Eperzan (sotagliflozin) - approved in 2020
  5. Insulin analogs:
    • Tresiba (insulin degludec) - approved in 2014
    • Basaglar (insulin glargine) - approved in 2014
    • Lusduna (insulin glargine) - approved in 2020
  6. Other medications:
    • Xigduo (dapagliflozin and metformin) - approved in 2014
    • Jardiance XR (empagliflozin) - approved in 2019
    • Rybelsus (semaglutide) - approved in 2020

These medications work in different ways to help manage blood sugar levels and may be used alone or in combination with other medications. It's important to note that each medication has its own benefits and risks, and the choice of medication will depend on individual patient needs and circumstances.